Is Mitotane classified as a targeted anticancer drug?

Mitotane is a drug used to treat adrenocortical cancer (ACC) and has unique pharmacological effects. Although it plays an important role in anti-cancer treatment, mitotane is not a typical targeted anti-cancer drug. Targeted drugs usually interfere with specific molecular markers or signaling pathways of cancer cells, while mitotane's mechanism of action is more likely to inhibit tumor growth by destroying the function of adrenocortical cells.

Specifically, mitotane can selectively damage the mitochondria of adrenocortical cells and inhibit the synthesis of adrenocortical hormones, thereby slowing down or inhibiting the proliferation of adrenocortical cancer cells. This mechanism is different from traditional chemotherapy drugs and targeted drugs, and is closer to the category of cytotoxic drugs. Therefore, mitotane is mainly classified as an adrenocortical inhibitor and anti-tumor drug, rather than a targeted therapy drug in the modern sense.

The clinical application of mitotane is mainly focused on the adjuvant treatment or late-stage treatment of patients with adrenocortical cancer. Because this cancer is rare and has a poor prognosis, mitotane has played an important role in prolonging survival and alleviating symptoms as a treatment option. Although it is not a targeted drug, it has irreplaceable value in the treatment of adrenocortical cancer.

In general, although mitotane is an effective anti-cancer drug, it does not belong to the category of targeted anti-cancer drugs due to its unique mechanism of action. Patients should reasonably evaluate the treatment plan and expected effects according to the guidance of their doctor when using it. With the continuous advancement of medical research, more precise targeted drugs may be used for the treatment of adrenocortical cancer in the future, enriching treatment options.

Reference materials:https://go.drugbank.com/drugs/DB00648